2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
05/02/16AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company’s Notch 3 antibody program. The No... 
Printer Friendly Version
03/21/16AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar. 21, 2016-- AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in which AVEO has granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitor... 
Printer Friendly Version
03/15/16AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create increased shareholder value. In 2016, we are squarely focused on furthering the execution of this strategy,” said Michael Bailey, president and chief ex... 
Printer Friendly Version
03/09/16AVEO to Present at the 28th Annual ROTH Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website a... 
Printer Friendly Version
03/01/16EUSA Pharma and AVEO Announce Submission of Marketing Authorization Application for Tivozanib in Advanced Renal Cell Carcinoma
HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2016-- EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC). The filing is based on tivozanib’s existing dataset and follows positive interactio... 
Printer Friendly Version
02/22/16AVEO Announces Acceptance of Registration Dossier for Tivozanib in RCC by the Ministry of Health of the Russian Federation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”) of the Russian Federation. The dossier was submitted in December 2015 by Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”). In Augu... 
Printer Friendly Version
02/02/16AVEO to Present at the 18th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section... 
Printer Friendly Version
01/06/16AVEO to Present at Biotech Showcase 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcas... 
Printer Friendly Version